Nls pharmaceutics announces new preclinical data for aex-2, expanding the therapeutic potential of its non-sulfonamide dual orexin receptor agonist platform

ZÜrich, switzerland , feb. 27, 2025 /prnewswire/ -- nls pharmaceutics ltd. (nasdaq: nlsp) (nasdaq: nlspw) ("nls" or the "company"), in collaboration with aexon labs inc. ("aexon labs"), is pleased to announce new preclinical findings on aex-2, reinforcing its potential as a first-in-class non-sulfonamide dual orexin receptor agonist ("doxa") for narcolepsy and related neurological disorders.
NLSP Ratings Summary
NLSP Quant Ranking